Owens P, O'Brien E
Ir Med J. 1998 Oct-Nov;91(5):158, 160-1.
What, finally can we conclude from the work to date regarding the use of CCB's? The large clinical trials here give a number of clear messages to the prescriber. Short-acting dihydropyridine CCB's are unproven as prophylactic agents in ischaemic heart disease. In patients with poor left ventricular function post-infarct, CCB's are associated with an unchanged or increased mortality. Use of medications in the treatment of hypertension should be with proven first-line therapeutic agents; beta-blockers, diuretics; and the long-acting dihydropyridine CCB's nifedipine GITS and nitrendipine. The final argument in the discussion over the safety or otherwise of calcium channel blockers will rest in the completion in the future of a number of prospective, randomised, place-controlled clinical drug trials. These trials are currently ongoing, and their results may not be available until after the year 2000.
到目前为止，就使用钙通道阻滞剂（CCB）的研究工作，我们最终能得出什么结论呢？这里的大型临床试验给开处方的医生传达了一些明确的信息。短效二氢吡啶类CCB作为缺血性心脏病的预防药物尚未得到证实。在心肌梗死后左心室功能较差的患者中，CCB与死亡率不变或增加有关。治疗高血压应使用已证实的一线治疗药物；β受体阻滞剂、利尿剂；以及长效二氢吡啶类CCB硝苯地平控释片和尼群地平。关于钙通道阻滞剂安全性与否的讨论的最终论据将取决于未来一些前瞻性、随机、安慰剂对照的临床药物试验的完成情况。这些试验目前正在进行，其结果可能要到2000年以后才会出来。
